Details

Autor(en) / Beteiligte

• Lemmerman, Luke R
• Balch, Maria H H
• Moore, Jordan T
• Alzate-Correa, Diego
• Rincon-Benavides, Maria A
• Salazar-Puerta, Ana
• Gnyawali, Surya
• Harris, Hallie N
• Lawrence, William
• Ortega-Pineda, Lilibeth
• Wilch, Lauren
• Risser, Ian B
• Maxwell, Aidan J
• Duarte-Sanmiguel, Silvia
• Dodd, Daniel
• Guio-Vega, Gina P
• McTigue, Dana M
• Arnold, W David
• Nimjee, Shahid M
• Sen, Chandan K
• Khanna, Savita
• Rink, Cameron
• Higuita-Castro, Natalia
• Gallego-Perez, Daniel

Titel

Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke

Ist Teil von

• Science advances, 2021-03, Vol.7 (12)

Ort / Verlag

United States: American Association for the Advancement of Science

Erscheinungsjahr

2021

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Ischemic stroke causes vascular and neuronal tissue deficiencies that could lead to substantial functional impairment and/or death. Although progenitor-based vasculogenic cell therapies have shown promise as a potential rescue strategy following ischemic stroke, current approaches face major hurdles. Here, we used fibroblasts nanotransfected with , , and ( ) to drive reprogramming-based vasculogenesis, intracranially, as a potential therapy for ischemic stroke. Perfusion analyses suggest that intracranial delivery of -nanotransfected fibroblasts led to a dose-dependent increase in perfusion 14 days after injection. MRI and behavioral tests revealed ~70% infarct resolution and up to ~90% motor recovery for mice treated with -nanotransfected fibroblasts. Immunohistological analysis confirmed increases in vascularity and neuronal cellularity, as well as reduced glial scar formation in response to treatment with -nanotransfected fibroblasts. Together, our results suggest that vasculogenic cell therapies based on nanotransfection-driven (i.e., nonviral) cellular reprogramming represent a promising strategy for the treatment of ischemic stroke.